Skip to main content

VALIDACION Y DESARROLLO DE UN BIOMARCADOR EFECTIVO A LA RESPUESTA TERAPEUTICA FRENTE A ANTIMETABOLITOS USADOS PARA EL TRATAMIENTO DE CANCER

PI17/00624

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2017
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION INSTITUTO INV GERMANS TRIAS I PUJOL
Execution centre FUNDACION IRSICAIXA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

JAK-STAT Pathway, A Novel Target to Tackle Viral Infections

  • Ezeonwumelu, I.J.|||0000-0003-4007-2212
  • García Vidal, Edurne|||0000-0003-0698-8710
  • Ballana, Ester|||0000-0002-5215-7363
Modulation of the antiviral innate immune response has been proposed as a putative cellular target for the development of novel pan-viral therapeutic strategies. The Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway is especially relevant due to its essential role in the regulation of local and systemic inflammation in response to viral infections, being, therefore, a putative therapeutic target. Here, we review the extraordinary diversity of strategies that viruses have evolved to interfere with JAK-STAT signaling, stressing the relevance of this pathway as a putative antiviral target. Moreover, due to the recent remarkable progress on the development of novel JAK inhibitors (JAKi), the current knowledge on its efficacy against distinct viral infections is also discussed. JAKi have a proven efficacy against a broad spectrum of disorders and exhibit safety profiles comparable to biologics, therefore representing good candidates for drug repurposing strategies, including viral infections.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Pharmacological modulation of SAMHD1 activity by CDK4/6 inhibitors improves anticancer therapy

  • Castellví, Marc
  • Felip, Eudald|||0000-0002-3812-1313
  • Ezeonwumelu, I.J.|||0000-0003-4007-2212
  • Badia, Roger|||0000-0003-3982-7577
  • García Vidal, Edurne|||0000-0003-0698-8710
  • Pujantell, Maria|||0000-0002-9471-5853
  • Gutiérrez-Chamorro, Lucía|||0000-0002-7649-951X
  • Teruel, Iris|||0000-0002-5563-6562
  • Martínez Cardús, Anna|||0000-0002-3937-8794
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Riveira Muñoz, Eva|||0000-0002-6396-1162
  • Margelí, Mireia|||0000-0003-3594-4530
  • Ballana, Ester|||0000-0002-5215-7363
Sterile alpha motif and histidine-aspartic acid domain-containing protein 1 (SAMHD1) is a dNTP triphosphohydrolase involved in the regulation of the intracellular dNTP pool, linked to viral restriction, cancer development and autoimmune disorders. SAMHD1 function is regulated by phosphorylation through a mechanism controlled by cyclin-dependent kinases and tightly linked to cell cycle progression. Recently, SAMHD1 has been shown to decrease the efficacy of nucleotide analogs used as chemotherapeutic drugs. Here, we demonstrate that SAMHD1 can enhance or decrease the efficacy of various classes of anticancer drug, including nucleotide analogues, but also anti-folate drugs and CDK inhibitors. Importantly, we show that selective CDK4/6 inhibitors are pharmacological activators of SAMHD1 that act by inhibiting its inactivation by phosphorylation. Combinations of a CDK4/6 inhibitor with nucleoside or folate antimetabolites potently enhanced drug efficacy, resulting in highly synergic drug combinations (CI < 0.04). Mechanistic analyses reveal that cell cycle-controlled modulation of SAMHD1 function is the central process explaining changes in anticancer drug efficacy, therefore providing functional proof of the potential of CDK4/6 inhibitors as a new class of adjuvants to boost chemotherapeutic regimens. The evaluation of SAMHD1 expression in cancer tissues allowed for the identification of cancer types that would benefit from the pharmacological modulation of SAMHD1 function. In conclusion, these results indicate that the modulation of SAMHD1 function may represent a promising strategy for the improvement of current antimetabolite-based treatments.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

CD32 expression is associated to T-cell activation and is not a marker of the HIV-1 reservoir

  • Badia, Roger|||0000-0003-3982-7577
  • Ballana, Ester|||0000-0002-5215-7363
  • Castellví, Marc
  • García Vidal, Edurne|||0000-0003-0698-8710
  • Pujantell, Maria|||0000-0002-9471-5853
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Prado, Julia G.|||0000-0002-5439-4645
  • Puig, Jordi|||0000-0002-4075-0346
  • Martinez, Miguel Angel|||0000-0002-6681-4950
  • Riveira Muñoz, Eva|||0000-0002-6396-1162
  • Este, José|||0000-0002-1436-5823
CD32 has been shown to be preferentially expressed in latently HIV-1-infected cells in an in vitro model of quiescent CD4 T cells. Here we show that stimulation of CD4+ T cells with IL-2, IL-7, PHA, and anti-CD3/CD28 antibodies induces T-cell proliferation, co-expression of CD32 and the activation of the markers HLA-DR and CD69. HIV-1 infection increases CD32 expression. 79.2% of the CD32+/CD4+ T cells from HIV+ individuals under antiretroviral treatment were HLA-DR+. Resting CD4+ T cells infected in vitro generally results in higher integration of provirus. We observe no difference in provirus integration or replication-competent inducible latent HIV-1 in CD32+ or CD32- CD4+ T cells from HIV+ individuals. Our results demonstrate that CD32 expression is a marker of CD4+ T cell activation in HIV+ individuals and raises questions regarding the immune resting status of CD32+ cells harboring HIV-1 proviruses. CD32 has been previously shown to be expressed preferentially by CD4 T cells latently harbouring HIV-1. Here the authors show that CD32 expression in CD4 T cells is associated with T cell activation, is up-regulated by HIV-1 infection and importantly does not appear to represent an enriched cellular niche for latent HIV-1.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Modulation of DNA Damage Response by SAM and HD Domain Containing Deoxynucleoside Triphosphate Triphosphohydrolase (SAMHD1) Determines Prognosis and Treatment Efficacy in Different Solid Tumor Types

  • Felip, Eudald|||0000-0002-3812-1313
  • Gutiérrez-Chamorro, Lucía|||0000-0002-7649-951X
  • Gómez, Maica
  • García Vidal, Edurne|||0000-0003-0698-8710
  • Romeo, Margarita|||0000-0003-1725-8115
  • Morán, Teresa
  • Layos, Laura
  • Pérez-Roca, Laia|||0000-0002-8400-1339
  • Riveira Muñoz, Eva|||0000-0002-6396-1162
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Fernández, Pedro Luis|||0000-0002-8618-4597
  • Mesia, Ricard|||0000-0002-3785-3563
  • Martínez Cardús, Anna|||0000-0002-3937-8794
  • Ballana, Ester|||0000-0002-5215-7363
  • Margelí, Mireia|||0000-0003-3594-4530
Ample evidence exists connecting dNTP pool dysregulation to cancer and genomic instability. SAMHD1, the unique dNTP triphosphohydrolase described in humans, has been proposed to play a key role in hematological cancers, although its value in advanced solid tumors has not yet been explored. Moreover, it has been proposed that SAMHD1 might fulfill the requirements of a driver gene in tumor development or might promote a so-called mutator phenotype. Here, we show that low SAMHD1 expression tumors show better prognosis in breast, ovarian, and lung advanced cancer. Moreover, low SAMHD1 expression is a positive predictive factor in lung and ovarian cancer treated with platin derivates and/or antimetabolites. In vitro evaluation of its underlying mechanism revealed that SAMHD1 KO cells presented enhanced susceptibility to DNA damage and subsequent induction of apoptosis of tumor cells. Our results provide strong evidence of the clinical importance of SAMHD1, becoming an interesting target for the development of personalized cancer treatments. SAMHD1 is a deoxynucleotide triphosphate (dNTP) triphosphohydrolase with important roles in the control of cell proliferation and apoptosis, either through the regulation of intracellular dNTPs levels or the modulation of the DNA damage response. However, SAMHD1's role in cancer evolution is still unknown. We performed the first in-depth study of SAMHD1's role in advanced solid tumors, by analyzing samples of 128 patients treated with chemotherapy agents based on platinum derivatives and/or antimetabolites, developing novel in vitro knock-out models to explore the mechanisms driving SAMHD1 function in cancer. Low (or no) expression of SAMHD1 was associated with a positive prognosis in breast, ovarian, and non-small cell lung cancer (NSCLC) cancer patients. A predictive value was associated with low-SAMHD1 expression in NSCLC and ovarian patients treated with antimetabolites in combination with platinum derivatives. In vitro, SAMHD1 knock-out cells showed increased γ-H2AX and apoptosis, suggesting that SAMHD1 depletion induces DNA damage leading to cell death. In vitro treatment with platinum-derived drugs significantly enhanced γ-H2AX and apoptotic markers expression in knock-out cells, indicating a synergic effect of SAMHD1 depletion and platinum-based treatment. SAMHD1 expression represents a new strong prognostic and predictive biomarker in solid tumors and, thus, modulation of the SAMHD1 function may constitute a promising target for the improvement of cancer therapy.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

SAMHD1 expression modulates innate immune activation and correlates with ovarian cancer prognosis

  • Gutiérrez-Chamorro, Lucía|||0000-0002-7649-951X
  • Felip, Eudald|||0000-0002-3812-1313
  • Bernat-Peguera, Adrià|||0000-0002-3108-0571
  • Ezeonwumelu, I.J.|||0000-0003-4007-2212
  • Teruel, Iris|||0000-0002-5563-6562
  • Martínez Cardús, Anna|||0000-0002-3937-8794
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Riveira Muñoz, Eva|||0000-0002-6396-1162
  • Romeo, Margarita|||0000-0003-1725-8115
  • Margelí, Mireia|||0000-0003-3594-4530
  • Ballana, Ester|||0000-0002-5215-7363
SAMHD1 is a deoxynucleotide triphosphate (dNTP) triphosphohydrolase which has been proposed as a putative prognostic factor in haematological cancers and certain solid tumours, although with controversial data. Here, we evaluate SAMHD1 function in ovarian cancer, both in vitro and in ovarian cancer patients. SAMHD1 expression was downregulated in ovarian cancer cell lines OVCAR3 and SKOV3 by RNA interference. Gene and protein expression changes in immune signalling pathways were assessed. SAMHD1 expression in ovarian cancer patients was evaluated by immunohistochemistry and survival analysis was performed according to SAMHD1 expression. SAMHD1 knockdown induced a significant upregulation of proinflammatory cytokines concomitant to increased expression of the main RNA-sensors, MDA5 and RIG-I, and interferon-stimulated genes, supporting the idea that the absence of SAMHD1 promotes innate immune activation in vitro. To assess the contribution of SAMHD1 in ovarian cancer patients, tumours were stratified in SAMHD1-low and SAMHD1-high expressing tumours, resulting in significantly shorter progression free survival (PFS) and overall survival (OS) in SAMHD1-high expression subgroup (p =0.01 and 0.04, respectively). SAMHD1 depletion correlates with increased innate immune cell signalling in ovarian cancer cells. In clinical samples, SAMHD1-low expressing tumors showed increased progression free survival and overall survival irrespective of BRCA mutation status. These results point towards SAMHD1 modulation as a new therapeutic strategy, able to enhance innate immune activation directly in tumour cells, leading to improved prognosis in ovarian cancer.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

SAMHD1 expression is a surrogate marker of immune infiltration and determines prognosis after neoadjuvant chemotherapy in early breast cancer

  • Gutiérrez-Chamorro, Lucía|||0000-0002-7649-951X
  • Felip, Eudald|||0000-0002-3812-1313
  • Castellà Fernández, Eva
  • Quiroga García, Vanesa
  • Ezeonwumelu, I.J.|||0000-0003-4007-2212
  • Angelats, Laura
  • Esteve, Anna|||0000-0002-1962-971X
  • Pérez-Roca, Laia|||0000-0002-8400-1339
  • Martínez Cardús, Anna|||0000-0002-3937-8794
  • Fernandez, Pedro Luis
  • Ferrando Díez, Angelica|||0000-0003-0206-7498
  • Pous, Anna
  • Bergamino, Milana|||0000-0002-1091-2711
  • Cirauqui, Beatriz|||0000-0002-0136-8056
  • Romeo, Marga
  • Teruel, Iris|||0000-0002-5563-6562
  • Mesia, Ricard|||0000-0002-3785-3563
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Riveira Muñoz, Eva|||0000-0002-6396-1162
  • Margelí, Mireia|||0000-0003-3594-4530
  • Ballana, Ester|||0000-0002-5215-7363
The lack of validated surrogate biomarkers is still an unmet clinical need in the management of early breast cancer cases that do not achieve complete pathological response after neoadjuvant chemotherapy (NACT). Here, we describe and validate the use of SAMHD1 expression as a prognostic biomarker in residual disease in vivo and in vitro. SAMHD1 expression was evaluated in a clinical cohort of early breast cancer patients with stage II-III treated with NACT. Heterotypic 3D cultures including tumor and immune cells were used to investigate the molecular mechanisms responsible of SAMHD1 depletion through whole transcriptomic profiling, immune infiltration capacity and subsequent delineation of dysregulated immune signaling pathways. SAMHD1 expression was associated to increased risk of recurrence and higher Ki67 levels in post-NACT tumor biopsies of breast cancer patients with residual disease. Survival analysis showed that SAMHD1-expressing tumors presented shorter time-to-progression and overall survival than SAMHD1 negative cases, suggesting that SAMHD1 expression is a relevant prognostic factor in breast cancer. Whole-transcriptomic profiling of SAMHD1-depleted tumors identified downregulation of IL-12 signaling pathway as the molecular mechanism determining breast cancer prognosis. The reduced interleukin signaling upon SAMHD1 depletion induced changes in immune cell infiltration capacity in 3D heterotypic in vitro culture models, confirming the role of the SAMHD1 as a regulator of breast cancer prognosis through the induction of changes in immune response and tumor microenvironment. SAMHD1 expression is a novel prognostic biomarker in early breast cancer that impacts immune-mediated signaling and differentially regulates inflammatory intra-tumoral response. The online version contains supplementary material available at 10.1007/s13402-023-00862-1.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

SARS-CoV-2 Infection Modulates ACE2 Function and Subsequent Inflammatory Responses in Swabs and Plasma of COVID-19 Patients

  • Gutiérrez-Chamorro, Lucía|||0000-0002-7649-951X
  • Riveira Muñoz, Eva|||0000-0002-6396-1162
  • Barrios, Clara|||0000-0003-0492-4107
  • Palau, Vanesa|||0000-0002-3210-7924
  • Nevot Banús, Maria|||0000-0003-4947-4648
  • Pedreño-López, Sònia|||0000-0002-1919-3530
  • Senserrich, Jordi|||0000-0002-8021-1718
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Cabrera Navarro, Cecilia|||0000-0002-9941-6828
  • Mitjà, Oriol|||0000-0003-3266-8868
  • Crespo, Marta|||0000-0001-6992-6379
  • Pascual, Julio|||0000-0002-4735-7838
  • Riera Oliva, Marta|||0000-0003-4362-7965
  • Ballana, Ester|||0000-0002-5215-7363
Angiotensin converting enzyme 2 (ACE2) is a host ectopeptidase and the receptor for the SARS-CoV-2 virus, albeit virus-ACE2 interaction goes far beyond viral entry into target cells. Controversial data exists linking viral infection to changes in ACE2 expression and function, which might influence the subsequent induction of an inflammatory response. Here, we tested the significance of soluble ACE2 enzymatic activity longitudinally in nasopharyngeal swabs and plasma samples of SARS-CoV-2 infected patients, along with the induction of inflammatory cytokines. Release of soluble functional ACE2 increases upon SARS-CoV-2 infection in swabs and plasma of infected patients, albeit rapidly decreasing during infection course in parallel with ACE2 gene expression. Similarly, SARS-CoV-2 infection also induced the expression of inflammatory cytokines. These changes positively correlated with the viral load. Overall, our results demonstrate the existence of mechanisms by which SARS-CoV-2 modulates ACE2 expression and function, intracellular viral sensing and subsequent inflammatory response, offering new insights into ACE2 dynamics in the human upper respiratory tract and pointing towards soluble ACE2 levels as a putative early biomarker of infection severity.